Views & Analysis Case study: Ensuring safety by digitally linking prescriptio... Monitoring people who are on disease modifying drugs (DMDs) is paramount to providing safe, high-quality MS care.
News RNAi biotech City hauls in $200m in upsized IPO City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.